Content labelled as: Research

Cladribine: new oral treatment to be available for people with relapsing MS

Blog post

Source MS Society:

A new oral treatment for relapsing MS, called cladribine, will be made available on the NHS in England and Wales within the next three months.

Targeting Blood-clotting Protein Can Restore Brain’s Potential to Repair Myelin Layer, Study Shows

Blog post

Source Multiple Sclerosis News Today:

A blood-clotting protein called fibrinogen prevents myelin production and blocks the neuron remyelination repair process in mice, a study finds.

MS Society Research Talk 13th November

Blog post

Research Talk

Date: Monday 13th November 2017, Time: 10:30 - 13:30 Venue: The Salvation Army Hall Chalfont Close, Lower Earley, RG6 5HZ

Positive results for clinical trial in progressive MS

Blog post

Source MS Society:

Researchers in the US have proclaimed their initial test of ibudilast for MS a success.

Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis

Blog post

Source Labiotech.eu

BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research.

3D printing brain scans helps doctors with a tricky diagnosis

Blog post

Source Tech Crunch:

When there’s a problem in the brain, it pays to be precise — every millimeter counts with something like a tumor or blocked artery.

Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study

Blog post

Source Multiple Sclerosis News Today:

A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease.

Importantly,...

New study to look at impact of early treatment with aggressive DMTs

Blog post

Source MS Society:

A new study will investigate whether early treatment with aggressive disease modifying therapies (DMTs) could benefit people with MS.

Disarm Therapeutics to Begin Developing Therapy that Prevents Axonal Degeneration

Blog post

Source Multiple Sclerosis News Today:

Disarm Therapeutics has completed the first round of financing to develop a compound that prevents axonal degeneration in patients with multiple sclerosis (MS) and other neurodegenerative conditions.

European Commission reverses decision on drug, following QMUL research

Blog post

Source Queen Mary University of London:

A drug for multiple sclerosis (MS) has been granted a license by the European Commission, following evidence from Queen Mary University of London (QMUL) that it improves patients’ quality of life and is safer than previously thought.

Pages

Subscribe to Content labelled as: Research